Ironwood Pharmaceuticals
IRWD
202 hedge funds and large institutions have $1.84B invested in Ironwood Pharmaceuticals in 2020 Q2 according to their latest regulatory filings, with 29 funds opening new positions, 87 increasing their positions, 54 reducing their positions, and 18 closing their positions.
94% more call options, than puts
Call options by funds: $13.8M | Put options by funds: $7.15M
61% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 18
61% more repeat investments, than reductions
Existing positions increased: 87 | Existing positions reduced: 54
5% more funds holding
Funds holding: 193 → 202 (+9)
2% more capital invested
Capital invested by funds: $1.8B → $1.84B (+$36.1M)
1.12% less ownership
Funds ownership: 112.88% → 111.76% (-1.1%)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
+$66.5M |
| 2 |
State Street
Boston,
Massachusetts
|
+$24.4M |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
+$15.5M |
| 4 |
SPC
Slate Path Capital
New York
|
+$13.3M |
| 5 |
BlackRock
New York
|
+$11.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$56.7M |
| 2 |
EC
EcoR1 Capital
San Francisco,
California
|
-$45M |
| 3 |
Janus Henderson Group
London,
United Kingdom
|
-$39.3M |
| 4 |
MP
MFN Partners
Boston,
Massachusetts
|
-$34M |
| 5 |
UBS AM
Chicago,
Illinois
|
-$14.5M |
IRWD Hedge Fund Activity: Q2 2020 in Review
202 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Ironwood Pharmaceuticals (IRWD) for Q2 2020, worth a combined $1.84B — up 2% from $1.8B a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new IRWD positions and 18 closed out — a net gain of 11 holders — while 87 added to existing stakes and 54 trimmed.
The largest buyer was Camber Capital Management, opening a new position worth an estimated $66.5M. The largest seller was Fidelity Investments, cutting an estimated $56.7M.
- 202 institutional investors held Ironwood Pharmaceuticals (IRWD) as of Q2 2020, up from 193 in Q1 2020.
- Funds reported $1.84B of Ironwood Pharmaceuticals stock for Q2 2020, up 2% quarter-over-quarter.
- 29 funds opened new Ironwood Pharmaceuticals positions in Q2 2020 and 18 closed out, a net change of +11 holders.
- The largest Ironwood Pharmaceuticals buyer in Q2 2020 was Camber Capital Management, an estimated $66.5M added.
- The largest Ironwood Pharmaceuticals seller in Q2 2020 was Fidelity Investments, an estimated $56.7M sold.
Based on aggregated 13F filings for Q2 2020.